Side Effects of interferon beta-1a intramuscular injection: A Synthesis of Findings from 10 Studies

  1. Home
  2. Side Effects of interferon beta-1a intramuscular injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of interferon beta-1a intramuscular injection: A Synthesis of Findings from 10 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of interferon beta-1a intramuscular injection: A Synthesis of Findings from 10 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Interferon beta-1a is a commonly used treatment for relapsing-remitting multiple sclerosis (RRMS). Multiple studies have shown that it can be effective in reducing disease activity and improving disability status. However, there are potential side effects associated with interferon beta-1a, which can affect patients' willingness to take the medication.

A study in Iran ( 10 ) compared interferon beta-1a to intravenous immunoglobulin (IVIG) for treating RRMS. Both treatments showed benefits, but IVIG had a better safety profile. However, the study was limited by a small sample size and only followed patients for 12 months.

Another study ( 6 ) compared the efficacy and safety of a biosimilar interferon beta-1a to the original brand-name product. The biosimilar was found to be equally effective and safe.

Some studies have looked at specific side effects of interferon beta-1a. For example, a study ( 8 ) suggested that statins may counteract the effects of interferon beta-1a. Other studies have focused on the common side effect of flu-like symptoms. One study ( 2 ) showed that starting with a low dose and gradually increasing the dose of interferon beta-1a can reduce the severity and frequency of flu-like symptoms. Another study ( 3 ) found that pain medications can help alleviate flu-like symptoms.

Reasons for Side Effects

The side effects of interferon beta-1a are believed to be related to its ability to stimulate the immune system. Interferon beta-1a is a natural protein that helps the body fight infections. However, in some people, it can cause an overactive immune response, leading to inflammation and other side effects.

Common Side Effects

Injection Site Reactions

The most common side effect of interferon beta-1a is pain, redness, swelling, or itching at the injection site. These symptoms usually appear within a few hours of the injection and subside within a few days ( 10 , 4 ).

Flu-like Symptoms

Flu-like symptoms are also common side effects. These can include fever, chills, muscle aches, headaches, and fatigue ( 4 , 2 , 3 ). These symptoms are often more severe when treatment is first started but usually improve over time.

Other Side Effects

Other side effects of interferon beta-1a can include liver function abnormalities, hematologic abnormalities, neurological symptoms, and depression. These side effects are less common than injection site reactions and flu-like symptoms, but it is important to be aware of them.

Countermeasures for Side Effects

Injection Site Reactions

To help prevent injection site reactions, keep the injection site clean and apply cold compresses after the injection. Avoid massaging the injection site, as this can make the symptoms worse.

Flu-like Symptoms

If you experience flu-like symptoms, talk to your doctor. They may recommend over-the-counter pain relievers or other medications to help manage your symptoms. Getting plenty of rest and drinking fluids can also help.

Other Side Effects

If you experience any other side effects from interferon beta-1a, talk to your doctor. They can help you determine if the side effects are serious and recommend appropriate treatment.

Comparison of Studies

Commonalities in Studies

Most studies have shown that interferon beta-1a is effective for treating RRMS. They have also found that injection site reactions and flu-like symptoms are common side effects.

Differences in Studies

Studies have varied in their methods, such as the dose of interferon beta-1a, the length of treatment, and the criteria used to assess efficacy and safety. Therefore, it is difficult to directly compare the results of different studies. However, the overall pattern of findings suggests that interferon beta-1a can be beneficial for many patients with RRMS, but it is important to be aware of the potential side effects.

Precautions for Real-Life Applications

Interferon beta-1a is a powerful medication that can help manage RRMS, but it is important to understand the potential risks and benefits. Discuss any concerns you have with your doctor before starting treatment. Be sure to report any side effects you experience to your doctor so that they can provide appropriate management. Interferon beta-1a is not typically recommended for pregnant women or women who are breastfeeding.

Limitations of Current Research

Current research is limited by a number of factors. For example, many studies have been relatively small and have followed patients for a limited time. This means that we do not yet have a complete understanding of the long-term effects of interferon beta-1a. More research is needed to fully understand the risks and benefits of this medication.

Future Research Directions

Future research should focus on areas such as:

  • Identifying individuals who are most likely to benefit from interferon beta-1a and those who are at higher risk of side effects.
  • Developing strategies to minimize the risk of side effects.
  • Evaluating the long-term effects of interferon beta-1a.

Conclusion

Interferon beta-1a is an important treatment option for RRMS, but it is not without risks. Talk to your doctor to determine if this medication is right for you. Be sure to report any side effects you experience to your doctor so they can provide appropriate management.

Literature analysis of 10 papers
Positive Content
8
Neutral Content
1
Negative Content
1
Article Type
4
0
0
0
10
1.

Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice.

Author: JongenPeter Joseph, SindicChristian, SandersEvert, HawkinsStanley, LinssenWim, van MunsterErik, FrequinStephan, BormGeorge,

INFb-1a safety assessment

Data on adverse events from interferon beta-1a treatment in daily practice were assessed using quality assurance measures similar to phase III trials.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Validation StudyResearch to assess the validity and reliability of new measurement methods or diagnostic tests.

Language : English

2.

Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation.

Author: MatsonMark A, ZimmermanThomas R, TuccilloDianne, TangYongqiang, DeykinAaron

Reduced flu-like symptoms

This study investigated the effects of dose titration on flu-like symptoms, a common side effect of interferon beta therapy. The study found that dose titration was effective in reducing the severity and incidence of flu-like symptoms during the initial 8 weeks of treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study.

Author: BrandesDavid W, BigleyKim, HornsteinWilliam, CohenHart, AuWilliam, ShubinRichard

Reduced flu-like symptoms

Acetaminophen and ibuprofen were equally effective in controlling flu-like symptoms associated with IFNbeta treatment. The combination of initial dose titration and analgesic administration may be useful for the reduction of flu-like symptoms with IFNbeta-1a therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient.

Author: OzdenM G, ErelA, ErdemO, OztasM O

Cutaneous necrosis
Dermal fibrosis

This case report describes cutaneous necrosis and dermal fibrosis following intramuscular interferon-beta1a injections in a multiple sclerosis patient.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.

Author: NafissiShahriar, AzimiAmirreza, Amini-HarandiAli, SalamiShiva, shahkaramiMohammad Amir, HeshmatRamin

Effective RRMS treatment
Safe RRMS treatment

CinnoVex, a biosimilar form of interferon beta-1a, was shown to be safe and effective as an alternative to Avonex in treating relapsing remitting multiple sclerosis (RRMS).

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.

Author: Weinstock-GuttmanBianca, BhasiKavitha, BadgettDarlene, Tamaño-BlancoMiriam, MinhasMiranda, FeichterJoan, PatrickKara, MunschauerFrederick, BakshiRohit, RamanathanMurali

MS treatment

This study characterized gene expression profiles in peripheral blood mononuclear cells of 22 relapsing multiple sclerosis (MS) patients receiving interferon-beta1a (IFN-beta) therapy. Gene expression was analyzed after the first dose and upon chronic dosing, as well as differences between good responders and partial responders. Results showed that approximately 35% of genes were up-regulated and 65% were down-regulated after IFN-beta treatment. Differences in gene expression profiles between good responders and partial responders were observed in pathways involved in immune response and cell signaling.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

8.

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.

Author: RudickR A, PaceA, RaniM R S, HydeR, PanzaraM, AppachiS, ShrockJ, MaurerS L, CalabresiP A, ConfavreuxC, GalettaS L, LublinF D, RadueE-W, RansohoffR M

Extremity pain
Fatigue
Hepatic transaminase increase

Statin therapy did not appear to affect the clinical effects of interferon beta-1a in patients with relapsing-remitting multiple sclerosis or the primary molecular response to interferon beta treatment.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran.

Author: KalanieHossein, GharagozliKurosh, HemmatieAbolfazl, GhorbanieMehdie, KalanieAmir Reza

Improved disability status
Reduced relapse rate

This study compared the efficacy and safety of interferon beta-1a (Avonex) and intravenous immunoglobulin (IVIG) for treating relapsing-remitting multiple sclerosis in Iranian patients. Both treatments effectively reduced relapse rate, but IVIG demonstrated a slightly better safety profile and led to a greater decrease in disability score.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.